Fuzzy am I missing something ? My understanding is that Resverlogix sought phase 3 trial in europe as they could not get a phase 3 qualification from FDA (as category was not well established "epigenetics" I believe they (FDA) was thinking aout renal /oncology? memory ??

Also if phase 3 is successful in europe US regulators would accept trial with new announced fast track method of acceptance for allowing drug to be sold throughout the United States and most likely Canada

What other FDA approval (s) are you hoping to see in the short term ?

Stock2740 (board response appreciated)